COGT
Price:
$9.67
Market Cap:
$1.07B
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 a...[Read more]
Industry
Biotechnology
IPO Date
2018-03-29
Stock Exchange
NASDAQ
Ticker
COGT
According to Cogent Biosciences, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 988.95M. This represents a change of 38.30% compared to the average of 715.05M of the last 4 quarters.
The mean historical Enterprise Value of Cogent Biosciences, Inc. over the last ten years is 119.90M. The current 988.95M Enterprise Value has changed 82.38% with respect to the historical average. Over the past ten years (40 quarters), COGT's Enterprise Value was at its highest in in the September 2024 quarter at 1.11B. The Enterprise Value was at its lowest in in the September 2020 quarter at -31540039.20.
Average
119.90M
Median
48.65M
Minimum
-112540483.89
Maximum
558.79M
Discovering the peaks and valleys of Cogent Biosciences, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 1.09%
Maximum Annual Enterprise Value = 558.79M
Minimum Annual Increase = -202.88%
Minimum Annual Enterprise Value = -112540483.89
Year | Enterprise Value | Change |
---|---|---|
2023 | 434.01M | -22.33% |
2022 | 558.79M | 382.63% |
2021 | 115.78M | -202.88% |
2020 | -112540483.89 | 1.09% |
2019 | -9446163.84 | -117.54% |
2018 | 53.87M | 10.72% |
2017 | 48.65M | 148.56% |
2016 | 19.57M | -166.16% |
The current Enterprise Value of Cogent Biosciences, Inc. (COGT) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
369.53M
5-year avg
197.32M
10-year avg
119.90M
Cogent Biosciences, Inc.’s Enterprise Value is greater than Larimar Therapeutics, Inc. (401.63M), greater than Kura Oncology, Inc. (786.00M), less than Kiniksa Pharmaceuticals, Ltd. (1.45B), less than Cerevel Therapeutics Holdings, Inc. (8.24B), less than IDEAYA Biosciences, Inc. (2.02B), greater than AnaptysBio, Inc. (521.12M), greater than MeiraGTx Holdings plc (470.30M), less than Keros Therapeutics, Inc. (2.21B), greater than Homology Medicines, Inc. (-103303255.00), greater than Sana Biotechnology, Inc. (560.75M), greater than Olema Pharmaceuticals, Inc. (506.70M), greater than Cullinan Oncology, Inc. (639.85M), greater than aTyr Pharma, Inc. (138.44M), greater than Zentalis Pharmaceuticals, Inc. (276.36M), less than Syndax Pharmaceuticals, Inc. (1.20B), greater than KalVista Pharmaceuticals, Inc. (426.20M), greater than Mersana Therapeutics, Inc. (267.65M), greater than Ventyx Biosciences, Inc. (162.11M), less than Protagonist Therapeutics, Inc. (2.29B), less than Verona Pharma plc (3.08B),
Company | Enterprise Value | Market cap |
---|---|---|
401.63M | $431.33M | |
786.00M | $818.85M | |
1.45B | $1.54B | |
8.24B | $8.19B | |
2.02B | $2.40B | |
521.12M | $696.21M | |
470.30M | $506.43M | |
2.21B | $2.72B | |
-103303255.00 | $3.02M | |
560.75M | $591.66M | |
506.70M | $540.89M | |
639.85M | $739.49M | |
138.44M | $131.12M | |
276.36M | $277.22M | |
1.20B | $1.33B | |
426.20M | $461.56M | |
267.65M | $315.01M | |
162.11M | $212.84M | |
2.29B | $2.41B | |
3.08B | $3.29B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Cogent Biosciences, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Cogent Biosciences, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Cogent Biosciences, Inc.'s Enterprise Value?
What is the highest Enterprise Value for Cogent Biosciences, Inc. (COGT)?
What is the 3-year average Enterprise Value for Cogent Biosciences, Inc. (COGT)?
What is the 5-year average Enterprise Value for Cogent Biosciences, Inc. (COGT)?
How does the current Enterprise Value for Cogent Biosciences, Inc. (COGT) compare to its historical average?